Intravenous Iron Supplement for Iron Deficiency in Cardiac Transplant Recipients

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 13 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2022 Results of an analysis assessed the determinants of iron status in the 102 IronIC participants to better define iron deficiency in the HTx population published in the Clinical Transplantation
28 Apr 2021 Results assessing the prespecified secondary outcome health related quality of life (HRQoL) in Iron deficient Heart transplant recipients receiving intravenous ferric derisomaltose, presented at the 41st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
23 Jan 2021 Primary endpoint (Peak oxygen consumption) has not been met, as per results published in the Journal of Heart and Lung Transplantation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com